Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cytoplasmic protein NCK1 (Nck1) is a ubiquitously expressed adaptor protein consisting of three N-terminal SH3 domains and one C-terminal SH2 domain, serving as a critical link between tyrosine kinase signaling and the actin cytoskeleton (UniProt P16333). The Nck1 SH3.1 domain, the first of these modules, specifically recognizes and binds to proline-rich motifs (PxxP) on effector proteins such as the CD3 epsilon subunit of the T-cell receptor and the Guanine Nucleotide Exchange Factor SOS (Borroto et al., 2014; PubMed 24403530). This domain is essential for T-cell activation and the regulation of actin-mediated processes including cell migration, axonal growth, and podocyte stability in the kidney (Jones et al., 2006; PubMed 16531999). In pathological contexts, Nck1 SH3.1 is implicated in cancer progression, where it facilitates invasive signaling, and in autoimmune diseases where it mediates aberrant T-cell responses (Labelle-Dumais et al., 2011; PubMed 21490053). Therapeutic strategies targeting the Nck1 SH3.1 domain, such as the small molecule AX-024, focus on disrupting these specific protein-protein interfaces to treat inflammatory and autoimmune disorders (Borroto et al., 2016; PubMed 27910800).
Inhibition of protein-protein interactions by competitively binding to the SH3.1 domain, preventing its association with proline-rich motifs (PxxP) on effector proteins such as the CD3 epsilon subunit of the T-cell receptor.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cytoplasmic protein NCK1 (NCK1) SH3.1 domain (NCK1 SH3.1).